by Clinical Neuropsychologist | Saturday, February 22, 2025 | Dementia
Abstract Hippocampal atrophy on magnetic resonance imaging is an important biomarker in Alzheimer’s disease (AD). While hippocampal atrophy was thought to result from tau tangles in AD, different neuropathologies can lead to hippocampal atrophy, especially TAR...
by Clinical Neuropsychologist | Saturday, February 22, 2025 | Dementia
Abstract INTRODUCTION Specific features of subjective cognitive decline (SCD-plus) have been proposed to indicate an increased risk of preclinical Alzheimer’s disease (AD). However, few studies have examined how these features relate to AD biomarkers in...
by Clinical Neuropsychologist | Thursday, February 20, 2025 | Dementia
Abstract Neurodegenerative diseases (NDDs) pose a significant challenge in modern medicine due to their clinical heterogeneity, multifactorial etiologies, and frequent co-pathologies. Traditional diagnostic systems, based on clinical symptoms and post mortem findings,...
by Clinical Neuropsychologist | Wednesday, February 19, 2025 | Dementia
Abstract Recent evidence suggests that ocular testing holds promise as a non-invasive and cost-effective method for the early detection of Alzheimer’s disease (AD). After interviews with neurologists, optometrists, primary care physicians, and ophthalmologists,...
by Clinical Neuropsychologist | Wednesday, February 19, 2025 | Dementia
Abstract INTRODUCTION We examined how abnormal prefrontal neurophysiology and changes in gamma-aminobutyric acid-ergic (GABAergic) neurotransmission contribute to behavioral impairments in disorders associated with frontotemporal lobar degeneration (FTLD). METHODS We...
